ALDH1A2 suppresses epithelial ovarian cancer cell proliferation and migration by downregulating STAT3

被引:20
作者
Wang, Yichen [1 ]
Shao, Feng [1 ]
Chen, Lu [1 ]
机构
[1] Zhejiang Canc Hosp, Dept Gynecol Oncol, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2018年 / 11卷
关键词
ALDH1A2; epithelial ovarian cancer cell; STAT3; migration; cell growth; LOCALIZATION; GROWTH;
D O I
10.2147/OTT.S145864
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Epithelial ovarian cancer is the deadliest gynecological malignancy worldwide. A better understanding of epithelial ovarian cancer pathogenesis and the molecular mechanism underlying its metastasis may increase overall survival rates. Previous studies have indicated that aldehyde dehydrogenase 1 family member A2 (ALDH1A2) is a candidate tumor suppressor in epithelial ovarian cancer. However, the potential role of ALDH1A2 in the molecular mechanisms of epithelial ovarian cancer remains largely unclear. In the present study, we found lower expression of ALDH1A2 in high-grade epithelial ovarian cancer tissues than in low-grade epithelial ovarian cancer tissues. Overexpression of ALDH1A2 decreased the proliferation and migration of epithelial ovarian cancer cell lines, whereas ALDH1A2 knockdown significantly increased cell growth and migration. Moreover, upregulation of ALDH1A2 also reduced the activation of signal transducer and activator of transcription 3 (STAT3). In conclusion, these findings suggest that ALDH1A2 suppresses epithelial ovarian cancer cell proliferation and migration by downregulating STAT3.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 23 条
  • [1] Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer
    Brandt, Simone
    Samartzis, Eleftherios P.
    Zimmermann, Anne-Katrin
    Fink, Daniel
    Moch, Holger
    Noske, Aurelia
    Dedes, Konstantin J.
    [J]. BMC CANCER, 2017, 17
  • [2] CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
    Burgos-Ojeda, Daniela
    Wu, Rong
    McLean, Karen
    Chen, Yu-Chih
    Talpaz, Moshe
    Yoon, Euisik
    Cho, Kathleen R.
    Buckanovich, Ronald J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07) : 1717 - 1727
  • [3] Targeting transcription factor STAT3 for cancer prevention and therapy
    Chai, Edna Zhi Pei
    Shanmugam, Muthu K.
    Arfuso, Frank
    Dharmarajan, Arunasalam
    Wang, Chao
    Kumar, Alan Prem
    Samy, Ramar Perumal
    Lim, Lina H. K.
    Wang, Lingzhi
    Goh, Boon Cher
    Ahn, Kwang Seok
    Hui, Kam Man
    Sethi, Gautam
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 162 : 86 - 97
  • [4] Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6β1 integrin
    Colomiere, Michelle
    Findlay, Jock
    Ackland, Leigh
    Ahmed, Nuzhat
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (05) : 1034 - 1045
  • [5] STATs and gene regulation
    Darnell, JE
    [J]. SCIENCE, 1997, 277 (5332) : 1630 - 1635
  • [6] Fleury Hubert, 2015, Genes Cancer, V6, P378
  • [7] Strategies and Approaches of Targeting STAT3 for Cancer Treatment
    Furtek, Stefanie L.
    Backos, Donald S.
    Matheson, Christopher J.
    Reigan, Philip
    [J]. ACS CHEMICAL BIOLOGY, 2016, 11 (02) : 308 - 318
  • [8] Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
    Gritsina, Galina
    Xiao, Fang
    O'Brien, Shane W.
    Gabbasov, Rashid
    Maglaty, Marisa A.
    Xu, Ren-Huan
    Thapa, Roshan J.
    Zhou, Yan
    Nicolas, Emmanuelle
    Litwin, Samuel
    Balachandran, Siddharth
    Sigal, Luis J.
    Huszar, Dennis
    Connolly, Denise C.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 1035 - 1047
  • [9] The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study
    Huang, Ruixia
    Li, Xiaoran
    Holm, Ruth
    Trope, Claes G.
    Nesland, Jahn M.
    Suo, Zhenhe
    [J]. BMC CANCER, 2015, 15
  • [10] The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer
    Kim, H
    Lapointe, J
    Kaygusuz, G
    Ong, DE
    Li, CD
    van de Rijn, M
    Brooks, JD
    Pollack, JR
    [J]. CANCER RESEARCH, 2005, 65 (18) : 8118 - 8124